25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials

Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

10.25251/skin.5.supp.15 ◽

2021 ◽

Vol 5 (1) ◽

pp. s15

Author(s):

RB Warren ◽

A Blauvelt ◽

J Bagel ◽

KA Papp ◽

P Yamauchi ◽

...

Keyword(s):

Plaque Psoriasis ◽

Efficacy And Safety ◽

Phase 3 ◽

Active Comparator ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Bimekizumab versus Ustekinumab Efficacy Across Subgroups of Patients with Moderate to Severe Plaque Psoriasis: Results from the Multicenter, Randomized, Double-Blinded Phase 3 BE VIVID Trial

10.25251/skin.5.supp.16 ◽

2021 ◽

Vol 5 (1) ◽

pp. s16

Author(s):

B Strober ◽

JG Krueger ◽

N Magnolo ◽

R Vender ◽

DP Toth ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study

10.25251/skin.4.supp.82 ◽

2020 ◽

Vol 4 (6) ◽

pp. s82

Author(s):

K Reich ◽

K Papp ◽

A Blauvelt ◽

R Langley ◽

A Armstrong ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal

10.25251/skin.4.supp.83 ◽

2020 ◽

Vol 4 (6) ◽

pp. s83

Author(s):

K Gordon ◽

P Foley ◽

JG Krueger ◽

A Pinter ◽

K Reich ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study

10.25251/skin.3.supp.34 ◽

2019 ◽

Vol 3 ◽

pp. S34

Author(s):

Andrew Blauvelt ◽

Kim A Papp ◽

Joseph F Merola ◽

Alice B Gottlieb ◽

Nancy Cross ◽

...

Keyword(s):

Plaque Psoriasis ◽

Extension Study ◽

Severe Plaque Psoriasis ◽

Abstract not available.

Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64‐week phase 3 study (reSURFACE 1)

The Journal of Dermatology ◽

10.1111/1346-8138.15789 ◽

2021 ◽

Author(s):

Atsuyuki Igarashi ◽

Hidemi Nakagawa ◽

Akimichi Morita ◽

Yukari Okubo ◽

Shigetoshi Sano ◽

...

Keyword(s):

Plaque Psoriasis ◽

Japanese Patients ◽

Efficacy And Safety ◽

Phase 3 ◽

Severe Plaque Psoriasis

Patient‐reported outcomes with risankizumab versus fumaric acid esters in systemic therapy‐naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial

Journal of the European Academy of Dermatology and Venereology ◽

10.1111/jdv.17109 ◽

2021 ◽

Author(s):

D Thaçi ◽

AM Soliman ◽

K Eyerich ◽

A Pinter ◽

M Sebastian ◽

...

Keyword(s):

Clinical Trial ◽

Fumaric Acid ◽

Plaque Psoriasis ◽

Systemic Therapy ◽

Patient Reported Outcomes ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Fumaric Acid Esters ◽

Patient Reported ◽

Acid Esters

15190 Whole blood transcriptomic profiling in a phase 3 study of the efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2020.06.213 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB31

Author(s):

Shaojun Tang ◽

Arnaud Amzallag ◽

Robert Yang ◽

Peter H. Schafer

Keyword(s):

Plaque Psoriasis ◽

Whole Blood ◽

Efficacy And Safety ◽

Phase 3 ◽

Transcriptomic Profiling ◽

Severe Plaque Psoriasis

Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants

Journal of Drugs in Dermatology ◽

10.36849/jdd.5698 ◽

2021 ◽

Vol 20 (3) ◽

pp. 252-258

Author(s):

Seemal Desai ◽

Brad Glick ◽

James Del Rosso ◽

Susan Harris ◽

Abby Jacobson

Keyword(s):

Plaque Psoriasis ◽

Phase 3 ◽

Once Daily ◽

Severe Plaque Psoriasis

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Advances in Therapy ◽

10.1007/s12325-017-0521-z ◽

2017 ◽

Vol 34 (6) ◽

pp. 1327-1339 ◽

Cited By ~ 9

Author(s):

Sandra Adsit ◽

Enrique Rivas Zaldivar ◽

Howard Sofen ◽

Ignacio Dei-Cas ◽

César Maldonado-García ◽

...

Keyword(s):

Plaque Psoriasis ◽

Pooled Analysis ◽

Phase 3 ◽

Severe Plaque Psoriasis ◽

Hispanic Patients